Wells Fargo’s TG Therapeutics TGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$20.7M Buy
375,894
+43,174
+13% +$1.77M ﹤0.01% 1610
2026
Q1
$11.1M Sell
332,720
-62,960
-16% -$1.88M ﹤0.01% 1955
2025
Q4
$11.8M Buy
395,680
+123,013
+45% +$4.02M ﹤0.01% 1901
2025
Q3
$9.85M Sell
272,667
-43,922
-14% -$1.45M ﹤0.01% 2013
2025
Q2
$11.4M Buy
316,589
+23,049
+8% +$858K ﹤0.01% 1810
2025
Q1
$11.6M Sell
293,540
-37,863
-11% -$1.27M ﹤0.01% 1744
2024
Q4
$9.98M Buy
331,403
+152,682
+85% +$4.38M ﹤0.01% 1891
2024
Q3
$4.18M Buy
178,721
+23,047
+15% +$503K ﹤0.01% 2489
2024
Q2
$2.77M Buy
155,674
+75,851
+95% +$1.21M ﹤0.01% 2724
2024
Q1
$1.21M Buy
79,823
+15,375
+24% +$245K ﹤0.01% 3329
2023
Q4
$1.1M Sell
64,448
-146,165
-69% -$1.7M ﹤0.01% 3381
2023
Q3
$1.76M Buy
210,613
+65,637
+45% +$915K ﹤0.01% 2902
2023
Q2
$3.6M Buy
144,976
+11,999
+9% +$310K ﹤0.01% 2408
2023
Q1
$2M Buy
132,977
+104,129
+361% +$1.58M ﹤0.01% 2857
2022
Q4
$341K Sell
28,848
-6,745
-19% -$49K ﹤0.01% 3873
2022
Q3
$211K Sell
35,593
-10,853
-23% -$71.2K ﹤0.01% 4218
2022
Q2
$198K Sell
46,446
-45,215
-49% -$282K ﹤0.01% 4283
2022
Q1
$872K Sell
91,661
-50,150
-35% -$580K ﹤0.01% 4007
2021
Q4
$2.69M Buy
141,811
+47,609
+51% +$1.24M ﹤0.01% 3199
2021
Q3
$3.14M Buy
94,202
+26,294
+39% +$813K ﹤0.01% 3273
2021
Q2
$2.63M Sell
67,908
-53,174
-44% -$2.09M ﹤0.01% 3440
2021
Q1
$5.84M Sell
121,082
-40,330
-25% -$1.94M ﹤0.01% 2700
2020
Q4
$8.4M Buy
161,412
+28,429
+21% +$960K ﹤0.01% 2241
2020
Q3
$3.56M Buy
132,983
+4,221
+3% +$97.1K ﹤0.01% 2825
2020
Q2
$2.51M Buy
128,762
+67,547
+110% +$1.09M ﹤0.01% 3100
2020
Q1
$602K Sell
61,215
-45,485
-43% -$574K ﹤0.01% 3904
2019
Q4
$1.19M Buy
106,700
+29,630
+38% +$225K ﹤0.01% 3742
2019
Q3
$434K Buy
77,070
+20,739
+37% +$145K ﹤0.01% 4475
2019
Q2
$487K Sell
56,331
-16,080
-22% -$122K ﹤0.01% 4396
2019
Q1
$582K Sell
72,411
-3,889
-5% -$21K ﹤0.01% 4238
2018
Q4
$313K Buy
76,300
+32,254
+73% +$160K ﹤0.01% 4640
2018
Q3
$248K Sell
44,046
-844,722
-95% -$9.65M ﹤0.01% 4884
2018
Q2
$11.7M Buy
888,768
+849,233
+2,148% +$11.7M ﹤0.01% 1949
2018
Q1
$562K Buy
39,535
+4,460
+13% +$57K ﹤0.01% 4312
2017
Q4
$287K Sell
35,075
-19,066
-35% -$167K ﹤0.01% 4780
2017
Q3
$642K Sell
54,141
-781
-1% -$8.9K ﹤0.01% 4163
2017
Q2
$552K Sell
54,922
-607
-1% -$6.79K ﹤0.01% 4157
2017
Q1
$646K Sell
55,529
-75,739
-58% -$544K ﹤0.01% 4074
2016
Q4
$611K Buy
131,268
+113,145
+624% +$664K ﹤0.01% 4059
2016
Q3
$140K Sell
18,123
-252
-1% -$1.62K ﹤0.01% 4701
2016
Q2
$111K Sell
18,375
-2,549
-12% -$20.7K ﹤0.01% 4764
2016
Q1
$178K Sell
20,924
-337
-2% -$2.95K ﹤0.01% 4472
2015
Q4
$254K Buy
21,261
+6,414
+43% +$81K ﹤0.01% 4306
2015
Q3
$149K Buy
14,847
+3,947
+36% +$58.8K ﹤0.01% 4638
2015
Q2
$181K Buy
10,900
+6,465
+146% +$102K ﹤0.01% 4666
2015
Q1
$69K Sell
4,435
-1,122
-20% -$17K ﹤0.01% 4894
2014
Q4
$88K Buy
5,557
+2,599
+88% +$33.8K ﹤0.01% 4790
2014
Q3
$32K Sell
2,958
-591
-17% -$5.48K ﹤0.01% 5111
2014
Q2
$34K Buy
3,549
+3,545
+88,625% +$22.7K ﹤0.01% 5119
2014
Q1
$0 Hold
4
﹤0.01% 6069
2013
Q4
$0 Hold
4
﹤0.01% 5921
2013
Q3
$0 Hold
4
﹤0.01% 5838
2013
Q2
$0 Buy
+4
New +$26 ﹤0.01% 5697

Other funds holding TGTX

Wells Fargo's TGTX Position: Q2 2026 in Review

Wells Fargo increased its TG Therapeutics (TGTX) stake by 13% in Q2 2026, buying an estimated $1.77M and bringing the position to 375,894 shares worth $20.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1610.

Wells Fargo first reported a position in TGTX in Q2 2013 and has held it in 53 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Wells Fargo held 375,894 shares of TG Therapeutics worth $20.7M as of Q2 2026.
  • Wells Fargo bought 43,174 TG Therapeutics shares in Q2 2026, an estimated $1.77M.
  • TG Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #1610 holding.
  • Wells Fargo first reported a position in TG Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.